Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
- AZ to Invest $200 Mil. to Build New Factory in China
October 12, 2011
- Merck Receives FDA Approval for Fixed Dose Combination of Januvia, Simvastatin
October 12, 2011
- PACIFIC Study Finds Higher Rate of STEMI in ACS in Japanese
October 12, 2011
- Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
- Sales of Publicly Funded Vaccines Continue to Increase in August: Crecon Research & Consulting
October 11, 2011
- AZ to Reduce US HQ Staff by approx. 400
October 11, 2011
- Avastin Receives Add’l Indication for Breast Cancer: Chugai
October 10, 2011
- Onyx Submits NDA in US for Carfilzomib in MM: Ono
October 10, 2011
- Eisai, Abbott Japan File for Additional Indication for Humira
October 10, 2011
- CHMP Issues Positive Opinion on New ARB Edarbi: Takeda
October 10, 2011
- Cubicin 350 mg IV Inj. Launched for MRSA Infections: MSD
October 10, 2011
- Results of PIII Trial of Rotarix Published in US Journal Vaccine: GSK
October 10, 2011
- Tsuruha HD to Establish Drugstore Joint Venture in Thailand
October 10, 2011
- Teva, Kowa to Break Up Joint Venture After Just 3 Years
October 10, 2011
- MediciNova Announces Private Sale of Stock to Kissei
October 10, 2011
- Novartis Pharma Donates ¥21 Mil. for Free Medical Exams for Disaster Victims in Soma City
October 10, 2011
- Telavic Approved for Chronic Hepatitis C: MTPC
October 10, 2011
- Anti-emetic Proemend IV Infusion 150 mg Approved: Ono
October 10, 2011
- Ilaris Approved as Japan’s 1st CAPS Treatment: Novartis Pharma
October 10, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…